LOS ANGELES, May 28, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it will present findings from a preclinical study on exosomes, Capricor’s newly licensed platform technology, at the 11th International Symposium on Stem Cell Therapy and Cardiovascular Innovations, being held May 29-30, 2014 in Madrid, Spain. The preclinical study sponsored by Cedars-Sinai Medical Center showed that exosomes were able to improve cardiac function and reduce the damage resulting from a heart attack.
Help employers find you! Check out all the jobs and post your resume.
